SCHEMBL3579859

SCHEMBL3579859

Cc1nc(N)co1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL408183 0.71
SCHEMBL17810622 0.67
SCHEMBL12641736 0.67
SCHEMBL15483091 0.67
SCHEMBL7041522 0.67
SCHEMBL428940 0.67
SCHEMBL8279602 0.67
SCHEMBL10094142 0.67
SCHEMBL10771087 0.65
Formamide SCHEMBL16742780 0.65 ENPP3 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230321228-A1 VACCINE ADJUVANTS AND METHODS OF SYNTHESIZING AND USING THE SAME EUAGORE, LLC 2023-10-12 US disclosed
EP-4218785-A2 MITOCHONDRIA-TARGETING PEPTIDES Stealth BioTherapeutics Inc. (US) 2023-08-02 EP disclosed
WO-2023133321-A1 SMALL MOLECULE PEPTIDOMIMETIC FOR THE TREATMENT OF TAUOPATHIES STEALTH BIOTHERAPEUTICS INC. (US) 2023-07-13 WO disclosed
US-20230203030-A1 COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS ARVINAS OPERATIONS, INC. 2023-06-29 US disclosed
WO-2023069549-A1 METHODS AND COMPOSITIONS COMPRISING PEPTIDOMIMITICS FOR TREATING, PREVENTING, INHIBITING, AMELIORATING OR DELAYING THE ONSET OF OPHTHALMIC CONDITIONS STEALTH BIOTHERAPEUTICS INC. (US) 2023-04-27 WO disclosed
EP-3723783-B1 MITOCHONDRIA-TARGETING PEPTIDES STEALTH BIOTHERAPEUTICS INC (US) 2023-02-15 EP disclosed
WO-2021012018-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2021-01-28 WO disclosed
WO-2019118878-A1 MITOCHONDRIA-TARGETING PEPTIDES STEALTH BIOTHERAPEUTICS CORP. (MC) 2019-06-20 WO disclosed
WO-2013064518-A1 PESTICIDAL COMPOUNDS SYNGENTA PARTICIPATIONS AG (CH) 2013-05-10 WO disclosed
WO-2012065568-A1 AZO HETEROCYCLIC COMPOUND HAVING INSECTICIDAL ACTIVITY, AND PREPARATION AND APPLICATIONS THEREOF 华东理工大学 (CN) 2012-05-24 WO disclosed
WO-2010071853-A1 THIAZOLOPYRIDINE SIRTUIN MODULATING COMPOUNDS SIRTRIS PHARMACEUTICALS, INC. (US) 2010-06-24 WO disclosed
US-7666871-B2 3-Methyl-6-(4-{5-methyl-4-[2-(2-methyl-pyrrolidin-1-yl)-ethyl]-oxazol-2-yl}-phenyl)-pyridazine; for treatment of obesity, cognitive deficiencies, narcolepsy ELI LILLY AND COMPANY (US) 2010-02-23 US disclosed
EP-1786790-B1 OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES LILLY CO ELI (US) 2009-06-03 EP disclosed
EP-1871770-A1 ORTHO-TERPHENYL INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS Kalypsys, Inc. (US) 2008-01-02 EP disclosed
US-20070197604-A1 Oxazole derivatives as histamine h3 receptor agents,preparation and therapeutic uses ELI LILLY AND COMPANY 2007-08-23 US disclosed
EP-1786790-A1 OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2007-05-23 EP disclosed
US-20060252807-A1 Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders KALYPSYS, INC. 2006-11-09 US disclosed
WO-2006116355-A1 ORTHO-TERPHENYL INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS KALYPSYS, INC. (US) 2006-11-02 WO disclosed
WO-2006019833-A1 OXAZOLE DERIVATIVES AS HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2006-02-23 WO disclosed
CN-1697650-A Non-nucleoside reverse transcriptase inhibitors RIBAPHARM INC (US) 2005-11-16 CN disclosed